Garrido-Mantilla J, Sanhueza J, Alvarez J, Pittman J, Davies P, Torremorell M
Viruses. 2025; 17(2).
PMID: 40006995
PMC: 11860655.
DOI: 10.3390/v17020240.
Oluka G, Sembera J, Katende J, Ankunda V, Kato L, Kurshan A
Vaccines (Basel). 2025; 13(2).
PMID: 40006690
PMC: 11860332.
DOI: 10.3390/vaccines13020143.
Wang Z, Tian C, Zhu J, Wang S, Ao X, He Y
J Nanobiotechnology. 2025; 23(1):55.
PMID: 39881325
PMC: 11776166.
DOI: 10.1186/s12951-025-03156-w.
Sidney J, Kim A, de Vries R, Peters B, Meade P, Krammer F
mBio. 2024; 16(2):e0347924.
PMID: 39714185
PMC: 11796400.
DOI: 10.1128/mbio.03479-24.
Berber E, Ross T
Vaccines (Basel). 2024; 12(11).
PMID: 39591186
PMC: 11598945.
DOI: 10.3390/vaccines12111284.
Contribution of immunoglobulin products in influencing seasonal influenza infection and severity in antibody immune deficiency patients receiving immunoglobulin replacement therapy.
Ballow M, Ortiz-de-Lejarazu R, Quinti I, Miller M, Warnatz K
Front Immunol. 2024; 15:1452106.
PMID: 39502688
PMC: 11534824.
DOI: 10.3389/fimmu.2024.1452106.
Vaccination against rapidly evolving pathogens and the entanglements of memory.
Cobey S
Nat Immunol. 2024; 25(11):2015-2023.
PMID: 39384979
DOI: 10.1038/s41590-024-01970-2.
Preliminary Findings From the Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE I) Study: A Randomized Controlled Trial.
Cowling B, Wong S, Santos J, Touyon L, Ort J, Ye N
Clin Infect Dis. 2024; 79(4):901-909.
PMID: 39041887
PMC: 11478574.
DOI: 10.1093/cid/ciae380.
Antibody responses in blood and saliva post COVID-19 bivalent booster do not reveal an Omicron BA.4/BA.5- specific response.
Baker Jr R, Lawlor R, Smith M, Price J, Eaton A, Lover A
Front Immunol. 2024; 15:1401209.
PMID: 38812500
PMC: 11133519.
DOI: 10.3389/fimmu.2024.1401209.
Preliminary findings from the Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE I) Study: a Randomized Controlled Trial.
Cowling B, Wong S, Santos J, Touyon L, Ort J, Ye N
medRxiv. 2024; .
PMID: 38798684
PMC: 11118649.
DOI: 10.1101/2024.05.16.24307455.
Cellular and Molecular Immunity to Influenza Viruses and Vaccines.
Kasten-Jolly J, Lawrence D
Vaccines (Basel). 2024; 12(4).
PMID: 38675771
PMC: 11154265.
DOI: 10.3390/vaccines12040389.
Evaluation of Vaccine Immunogenicity-Correlates to Real-World Protection: Influenza.
Laszlofy C, Fazekas G, Barath Z, Vajo Z
Viruses. 2024; 16(3).
PMID: 38543806
PMC: 10975834.
DOI: 10.3390/v16030441.
Back to the Future: Immune Protection or Enhancement of Future Coronaviruses.
Bartels M, Sala Sole E, Sauerschnig L, Rijkers G
Microorganisms. 2024; 12(3).
PMID: 38543668
PMC: 10975256.
DOI: 10.3390/microorganisms12030617.
Enhancing antibody responses by multivalent antigen display on thymus-independent DNA origami scaffolds.
Wamhoff E, Ronsard L, Feldman J, Knappe G, Hauser B, Romanov A
Nat Commun. 2024; 15(1):795.
PMID: 38291019
PMC: 10828404.
DOI: 10.1038/s41467-024-44869-0.
The relationship between the number of COVID-19 vaccines and infection with Omicron ACE2 inhibition at 18-months post initial vaccination in an adult cohort of Canadian paramedics.
Yap J, Kayda I, Asamoah-Boaheng M, Haig S, Kirkham T, Cheskes S
Access Microbiol. 2023; 5(11).
PMID: 38074102
PMC: 10702377.
DOI: 10.1099/acmi.0.000725.v3.
Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ Failure, and Death: United States, 2022-2023.
Lewis N, Zhu Y, Peltan I, Gaglani M, McNeal T, Ghamande S
Clin Infect Dis. 2023; 78(4):1056-1064.
PMID: 38051664
PMC: 11487098.
DOI: 10.1093/cid/ciad677.
Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine.
Wang Q, Guo Y, Tam A, Valdez R, Gordon A, Liu L
Cell Rep Med. 2023; 4(11):101258.
PMID: 37909042
PMC: 10694617.
DOI: 10.1016/j.xcrm.2023.101258.
Risk of hospital admission and death from first-ever SARS-CoV-2 infection by age group during the Delta and Omicron periods in British Columbia, Canada.
Skowronski D, Kaweski S, Irvine M, Chuang E, Kim S, Sabaiduc S
CMAJ. 2023; 195(42):E1427-E1439.
PMID: 37903524
PMC: 10615343.
DOI: 10.1503/cmaj.230721.
Broad protective RBD heterotrimer vaccines neutralize SARS-CoV-2 including Omicron sub-variants XBB/BQ.1.1/BF.7.
Zhang Y, Kang X, Liu S, Han P, Lei W, Xu K
PLoS Pathog. 2023; 19(9):e1011659.
PMID: 37721934
PMC: 10538664.
DOI: 10.1371/journal.ppat.1011659.
Vaccine-induced neutralizing antibody responses to seasonal influenza virus H1N1 strains are not enhanced during subsequent pandemic H1N1 infection.
Mooij P, Mortier D, Aartse A, Murad A, Correia R, Roldao A
Front Immunol. 2023; 14:1256094.
PMID: 37691927
PMC: 10484506.
DOI: 10.3389/fimmu.2023.1256094.